Chlorotrianisene
Chlorotrianisene (CTA), also known as tri-p-anisylchloroethylene (TACE) and sold under the brand name Tace among others, is a nonsteroidal estrogen related to diethylstilbestrol (DES) which was previously used in the treatment of menopausal symptoms and estrogen deficiency in women and prostate cancer in men, among other indications, but has since been discontinued and is now no longer available. It is taken by mouth.
Clinical data | |
---|---|
Trade names | Tace, Estregur, Anisene, Clorotrisin, Merbentyl, Triagen, others |
Other names | CTA; Trianisylchloroethylene; tri-p-Anisylchloroethylene; TACE; tris(p-Methoxyphenyl)-chloroethylene; NSC-10108 |
AHFS/Drugs.com | Multum Consumer Information |
Routes of administration | By mouth |
Drug class | Nonsteroidal estrogen |
ATC code | |
Pharmacokinetic data | |
Metabolism | Mono-O-demethylation (liver CYP450) |
Metabolites | Desmethylchlorotrianisene |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.008.472 |
Chemical and physical data | |
Formula | C23H21ClO3 |
Molar mass | 380.87 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
CTA is an estrogen, or an agonist of the estrogen receptors, the biological target of estrogens like estradiol. It is a high-efficacy partial estrogen and shows some properties of a selective estrogen receptor modulator, with predominantly estrogenic activity but also some antiestrogenic activity. CTA itself is inactive and is a prodrug in the body.
CTA was introduced for medical use in 1952. It has been marketed in the United States and Europe. However, it has since been discontinued and is no longer available in any country.